In early October, the Japanese Heart Failure Society (JHFS) held its first annual scientific meeting since it published a focused update of the heart failure treatment guidelines in March jointly with the Japanese Circulation Society. The confab featured a series…
BUSINESS
Nesp Biosame Priced at 62.8-69.2% of Originator
A key reimbursement policy panel agreed in March to price the so-called “biosame” version of the Nesp (darbepoetin alfa) renal anemia drug at 70% of the originator - just as that for biosimilars, as opposed to 50% for generics -…
To read the full story
Related Article
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
BUSINESS
- Nobelpharma Plans Launch of 3 Products in US, China, Europe: R&D Head
October 27, 2021
- Solasia Grants Japan Rights for Darinaparsin to Nippon Kayaku, Ends Deal with Meiji
October 27, 2021
- Daiichi Sankyo, AstraZeneca to Launch PIII of DS-1062/Keytruda Combo
October 27, 2021
- Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
- Oncolys’ Oral COVID-19 Drug Effective in Hamster Model
October 27, 2021
If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…